GlobeNewswire

VeriTransfer(TM) Unveils the First Known Proof-of-Concept for a Blockchain Enabled Firearms Licence Verification and Ownership Transfer

Dela

Blockchain Enabled Firearms Solution Ensures Instant Verification of Ownership and Safe Transfer While Maintaining Data Privacy

  

 

TORONTO, July 12, 2018 (GLOBE NEWSWIRE) -- VeriTransfer(TM) today announced the completion of its Proof-of-Concept ("POC") of the first publicly announced Blockchain enabled solution that decentralizes the process of storing the ownership rights and transfer of firearms.

VeriTransfer(TM) is also pleased to announce that it will donate a percentage of all future revenues or the proceeds from any future sale of the company towards foundations whose mission is to end gun violence and build safer communities.

The Gun Epidemic & The Economic Impact

The United States hosts 4.4% of the world's population, but almost 50% of the 644 million civilian-owned guns globally are located in the U.S. Disturbingly, more American citizens have died as a result of gunshots in the U.S. since 1968 than on the battlefield of all the wars in American history from 1175 to 2015. In addition, the estimated annual cost of fatal and non-fatal gun violence to the U.S. was $229 billion, representing 1.4% of total GDP1.

There have been 154 mass shootings in the United States since January 1st, 2018. This includes 23 school shootings that have occurred as of June 30th, 2018 in the U.S. where someone was either hurt or killed. That averages out to more than one school shooting a week2.                                 

The Potential Bipartisan Solution

VeriTransfer's mission is to help increase public safety, mitigate firearm-related deaths, all while empowering firearm owners to safely manage the ownership of their firearms and maintain complete data privacy. The decentralized and private structure of the VeriTransfer system gives full ownership of firearm data to the licence holder, while empowering law-abiding citizens to reduce the flow of firearms into criminal or suicidal hands.

Mathieu Glaude, CEO of Northern Block, the Toronto-based blockchain product development company is excited about VeriTransfer's potential societal impact. "We see the management of firearms as a perfect use case for blockchain technologies. Empowering individuals and retailers to privately manage their firearms in a decentralized manner is powerful and it presents an optimal solution to the unresolved gun control problem." said Glaude.

"We are incredibly excited to be involved in a real-world use case of blockchain technologies that has the potential to save lives," said Kesem Frank, COO of AION. "This is all achieved while maintaining data privacy and has the potential to eliminate data silos within government agencies."

VeriTransfer is a distributed system that decentralizes the storage of the ownership of firearms. The application makes it easy for any licenced firearm owner/retailer to manage their firearm inventory. Additionally, firearm holders can use VeriTransfer to digitally store a Government-issued licence, if applicable. VeriTransfer makes it simple for users to transfer firearm ownership at point-of-sale (B2B or B2C) or between licence holders (C2C) by scanning a QR code of the purchaser's licence using their mobile device. Additionally, firearm retailers can use VeriTransfer to perform licence eligibility checks prior to transferring firearm ownership to another person (e.g., selling a restricted firearm).

VeriTransfer is not a gun registry, it's a decentralized application that gives full ownership of firearm data to the licence owner. Firearm owners can be confident that their firearm data remains private and in their control at all times. Details about someone's identity, firearm licence (if applicable), and firearm ownership remain fully confidential and can only be accessed by external parties if consent is provided.

With blockchain technologies, the VeriTransfer decentralized application (dApp) uses permissioned smart contracts for users to access data from the blockchain. Firearms are turned into unique digital tokens, similar to the ERC-721 non-fungible token standard developed for Ethereum. These unique tokens are tied to engraved serial numbers or RFID-chipped firearms. Firearm ownership can be transferred between licence holders by sending these tokens electronically between the blockchain addresses of the licence holders. There's no need for users to acquire tokens, since they are automatically created through the system every time a firearm is added to the network.

Technology Overview

AION Blockchain

AION is an all-in-one blockchain network that enables hybrid architectures, scalability and interoperability for solutions built on top of it. AION allows building interoperable permissioned blockchains that has the ability to scale to an enterprise level.

Key Smart Contracts

Many functions of VeriTransfer (TM) rely on smart contracts within AION. A smart contract is a collection of code and data that resides on a specific blockchain address. They can facilitate, verify and enforce access to blockchain data between different users. Smart contracts can be described as a specific data slot on a blockchain that can be queried and changed by calling its functions. 

In VeriTransfer (TM), a firearm licence holder's data is managed through the following smart contracts: 

1. Licensing Smart Contract. Anytime a firearm licence is issued to an individual, a transaction is sent to VeriTransfer's permissioned blockchain. This smart contract records the fact that a person has a licence and stores the hashed validation of this fact to the permissioned blockchain. This allows for immutable track records of firearm holders to be kept on the blockchain.

2. Firearms Smart Contract. This maintains the record of gun ownership represented by a digital token within the contract and associates it with a specific individual. Retailers and firearms holders can pass the ownership from one to another, and the smart contract will facilitate the transfer of the digital token between users that are registered on a blockchain and have a blockchain address.

These two smart contracts interact with one another. Every new firearm registered in the system creates a new unique token that can be associated with a dealer's / individual's blockchain address.

Conclusion

The completion of the VeriTransfer (TM) Proof-of Concept is significant, as this process and key technology can be replicated in a bespoke manner for the US market, while dually maintaining data privacy without violating the Second Amendment of the United States Constitution. VeriTransfer is currently in discussions with various parties in order to commence a Pilot Project in Canada and/or the United States with selected firearms dealers and government agencies.  You can find a link to our Whitepaper and video demo of the application here:  Veritransfer.io

About VeriTransfer (TM)

VeriTransfer (TM), is the first known Blockchain enabled distributed system that decentralizes the process of the storage of the ownership rights, and transfer of firearms.

Key Contacts

Mark Lawson
VeriTransfer(TM) 
T: +1 647 256 1986 
mark@veritransfer.io

Mathieu Glaude
CEO, Northern Block Inc.
T: +1 647 991 8863
mathieu@northernblock.ca

Kesem Frank
COO, AION
T: +1 647 970 3736
kesem@mavennet.com

References:

  1. Michelle Singletary, The Washington Post, February 22, 2018; Mother Jones Report.
  2. Gun Violence Archive, 2018.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/830e7a9e-b315-46f6-8a35-a0b46d84dc81




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VeriTransfer via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum